Colposcopic Management of Abnormal Cervical Cytology and Histology

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 12, 2012, Pages 1188-1202

  Bentley, James ^a   Bertrand, Monique ^a   Brydon, Lizabeth ^a   Gagné, Hélène ^a   Hauck, Brian ^a   Mayrand, Marie Hélène ^a   McFaul, Susan ^a   Power, Patti ^a   Schepansky, Alexandra ^a   Straszak Suri, Marina ^a   Colgan, Terry ^a   Geldenhuys, Laurette ^a   Heywood, Mark ^a   Howlett, Roberta ^b   Kapusta, Linda ^a   Kupets, Rachel ^a   Murphy, Joan ^a   Nation, Jill ^a   Senikas, Vyta ^a   Shier, Michael ^a  

^a NONE   (Canada)

^b NONE   (Canada)

Author keywords

Abnormalities; Cervical cancer; Cervical cytology; Colposcopy; Follow up; Guidelines; Treatment

Indexed keywords

ABNORMAL LABORATORY RESULT; ADENOCARCINOMA IN SITU; ARTICLE; CANADA; COLPOSCOPY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HISTOLOGY; HUMAN; PAPANICOLAOU TEST; PRACTICE GUIDELINE; RISK REDUCTION; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; WART VIRUS; CYTODIAGNOSIS; DISEASE MANAGEMENT; MASS SCREENING; METHODOLOGY; PATHOLOGY; PRECANCER; RISK ASSESSMENT; UTERINE CERVIX TUMOR; HISTOPATHOLOGY;

COLPOSCOPY; CYTODIAGNOSIS; DISEASE MANAGEMENT; FEMALE; HUMANS; MASS SCREENING; PRECANCEROUS CONDITIONS; RISK ADJUSTMENT; UTERINE CERVICAL NEOPLASMS;

EID: 84971414894     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35468-8     Document Type: Article

References (95)

1. Canadian Cancer Society's Steering Committee Canadian cancer statistics 2009, Available at:, Accessed October 11, 2012. https://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/Past%20statistics.aspx?sc_lang=en.
2. International Agency for Research on Cancer, World Health Organization. IARC handbooks of cancer prevention: cervix cancer screening 2005, IARC Press, Lyon.
3. Ferris D.G., Cox J.T., O'Connor D.M., Wright V.C., Foerster J. Modern colposcopy textbook and atlas 2004, Kendall/Hunt Publishing Company, Dubuque IA. 2nd ed.
4. Working Group of Cervical Screen Singapore Management guidelines for abnormal Pap smear & invasive disease of the cervix 2002, Available at:, Accessed October 11, 2012. http://www.hpb.gov.sg/data/hpb.home/files/pro/cervicalscreen/managementguidelines_papsmear.pdf.
5. National Health Australian, Research Council Medical Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities 2005, Available at:, Accessed October 2012. http://www.nhmrc.gov.au/guidelines/publications/wh39.
6. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D., et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007, 11(4):223-239.
7. National Health Service Colposcopy and programme management: guidelines for the NHS Cervical Screening Programme 2010, Available at, Accessed February 28, 2011. http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.html, 2nd edition.
8. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., et al. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann Oncol 2010, 21(3):448-458.
9. Murphy K.J. Screening for cervical cancer. In: Canadian consensus guidelines in human papillomavirus. SOGC clinical practice guideline no. 196, August 2007. J Obstet Gynaecol Can 2007, 29(3):27-36. Suppl.
10. Moscicki A.B., Cox J.T. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis 2010, 14(1):73-80.
11. Institut nationale de santé publique Québec Recommendations on optimizing cervical cancer screening in Québec 2009, Available at:, Accessed March11, 2011. http://www.inspq.qc.ca/pdf/publications/1081_CervicalScreening.pdf.
12. Alberta Health Services Alberta Cervical Cancer Screening: Clinical Practice Guidelines and Management of Abnormal Cytology 2009, Available at:, Accessed March 11, 2011. http://www.screeningforlife.ca/_files/file.php?fileid=filenrNvasUkRV&filename=file_CC_CPG_Summary_Chart_LowR_Mar_2010.pdf.
13. Murphy J., Kennedy E.B., Dunn S., McLachlin M., Fung Kee Fung M., Gzik D., et al. Cervical screening: a guideline for clinical practice in Ontario. J Obstet Gynaecol Can 2012, 34(5):453-458.
14. Bornstein J., Bentley J., Bosze P., Girardi F., Haefner H., Menton M., et al. 2011 Colposcopic Terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012, 120(1):166-172.
15. Gage J.C., Hanson V.W., Abbey K., Dippery S., Gardner S., Kubota J., et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006, 108(2):264-272.
16. Zuchna C., Hager M., Tringler B., Georgoulopoulos A., Ciresa-Koenig A., Volgger B., et al. Diagnostic accuracy of guided cervical biopsies:a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol 2010, 203(4):321-326.
17. Gage J.C., Duggan M.A., Nation J.G., Gao S., Castle P.E. Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations. Am J Obstet Gynecol 2010, 203(5):481-489.
18. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003, 188(6):1393-1400.
19. TOMBOLA Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. BMJ 2009, 339. b2546.
20. Arbyn M., Dillner J., Van Ranst M., Buntinx F., Martin-Hirsch P., Paraskevaidis E. Re: Have we resolved how to triage equivocal cervical cytology?. J Natl Cancer Inst 2004, 96(18):1401-1402. author reply 1402.
21. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004, 96(4):280-293.
22. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CiN: an update of pooled evidence. Gynecol Oncol 2005, 99(3 Suppl 1):7-11.
23. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of metaanalyses. Vaccine 2006, 24(Suppl 3):78-79. Chapter 9.
24. Barreth D., Schepansky A., Capstick V., Johnson G., Steed H., Faught W. Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a result not to be ignored. J Obstet Gynaecol Can 2006, 28(12):1095-1098.
25. Mokhtar G.A., Delatour N.L., Assiri A.H., Gilliatt M.A., Senterman M., Islam S. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: cytohistologic correlation study with diagnostic pitfalls. Acta Cytol 2008, 52(2):169-177.
26. Massad L.S., Collins Y.C., Meyer P.M. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol Oncol 2001, 82(3):516-522.
27. Dunn T.S., Burke M., Shwayder J. A "see and treat" management for high- grade squamous intraepithelial lesion pap smears. J Low Genit Tract Dis 2003, 7(2):104-106.
28. Tam K.F., Cheung A.N., Liu K.L., Ng T.Y., Pun T.C., Chan Y.M., et al. A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. Gynecol Oncol 2003, 91(3):603-607.
29. Daniel A., Barreth D., Schepansky A., Johnson G., Capstick V., Faught W. Histologic and clinical significance of atypical glandular cells on pap smears. Int J Gynaecol Obstet 2005, 91(3):238-242.
30. Castle P.E., Fetterman B., Poitras N., Lorey T., Shaber R., Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010, 115(2):243-248. Pt 1.
31. Zhao C., Florea A., Onisko A., Austin R.M. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic women's hospital laboratory employing sensitive screening methods. Gynecol Oncol 2009, 114(3):383-389.
32. Schnatz P.F., Guile M., O'Sullivan D.M., Sorosky J.I. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006, 107(3):701-708.
33. Ullal A., Roberts M., Bulmer J.N., Mathers M.E., Wadehra V. The role of cervical cytology and colposcopy in detecting cervical glandular neoplasia. Cytopathology 2009, 20(6):359-366.
34. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362(9399):1871-1876.
35. Castle P.E., Fetterman B., Thomas Cox J., Shaber R., Poitras N., Lorey T., et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010, 116(1):76-84.
36. Wetta L.A., Matthews K.S., Kemper M.L., Whitworth J.M., Fain E.T., Huh W.K., et al. The management of cervical intraepithelial neoplasia during pregnancy: is colposcopy necessary?. J Low Genit Tract Dis 2009, 13(3):182-185.
37. Kohan S., Beckman E.M., Bigelow B., Klein S.A., Douglas G.W. The role of colposcopy in the management of cervical intraepithelial neoplasia during pregnancy and postpartum. J Reprod Med 1980, 25(5):279-284.
38. Ries L.A.G., Melbert D., Krapcho M., Mariotto A., Miller B.A., Feuer E.J., et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute 2007, Bethesda, MD, Available at:, Accessed October 11, 2012. http://seer.cancer.gov/csr/1975_2004.
39. Mount S.L., Papillo J.L. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999, 103(3).
40. Moscicki A.B., Ma Y., Wibbelsman C., Darragh T.M., Powers A., Farhat S., et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010, 116(6):1373-1380.
41. Le T., Hopkins L., Menard C., Hicks-Boucher W., Lefebvre J., Fung Kee Fung M. Psychologic morbidities prior to loop electrosurgical excision procedure in the treatment of cervical intraepithelial neoplasia. Int J Gynecol Cancer 2006, 16(3):1089-1093.
42. Arbyn M., Kyrgiou M., Simoens C., Raifu A.O., Koliopoulos G., Martin-Hirsch P., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008, 337:1284.
43. Samson S.L., Bentley J.R., Fahey T.J., McKay D.J., Gill G.H. The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol 2005, 105(2):325-332.
44. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
45. Kohli M., Ferko N., Martin A., Franco E.L., Jenkins D., Gallivan S., et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007, 96(1):143-150.
46. Cutts F.T., Franceschi S., Goldie S., Castellsague X., de Sanjose S., Garnett G., et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007, 85(9):719-726.
47. Rogoza R.M., Ferko N., Bentley J., Meijer C.J., Berkhof J., Wang K.L., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 2008, 26(5):46-58. Suppl.
48. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRiCiA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
49. ACOG Committee on Gynecological Practice. ACOG committee opinion No. 431: routine pelvic examination and cervical cytology screening. Obstet Gynecol 2009, 113(5):1190-1193.
50. ACOG Committee on Practice Bulletins-Gynecology. Cervical cytology screening. ACOG Practice Bulletin no. 109. Obstet Gynecol 2009, 114(6):1409-1420.
51. Darragh T.M., Colgan T.J., Cox J.T., Heller D.S., Henry M.R., Luff R.D., et al. LAST Project Work Groups. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012, 16(3):205-242.
52. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. int J Gynecol Pathol 1993, 12(2):186-192.
53. Kyrgiou M., Tsoumpou i., Vrekoussis T., Martin-Hirsch P., Arbyn M., Prendiville W., et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev 2006, 32(7):516-523.
54. Petry K.U. Management options for cervical intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol 2011, 25(5):641-651.
55. Prendiville W. The treatment of CIN: what are the risks?. Cytopathology 2009, 20(3):145-153.
56. Moscicki A.B., Shiboski S., Hills N.K., Powell K.J., Jay N., Hanson E.N., et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004, 364(9446):1678-1683.
57. Stoler M.H., Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285(11):1500-1505.
58. The Society for Colposcopy and Cervical Pathology of Singapore. Structured colposcopy training programme and registration forms 2012, Available at:, Accessed October 11. http://www.sccps.org/training.htm.
59. Jones R.W., Best D.V., Cox B., Fitzgerald N.W., Hill M., Jennings P., et al. Guidelines for the management of women with abnormal cervical smears1998. N Z Med J 2000, 113(1109):168-171.
60. Royal College of Obstetricians and Gynaecologists. Standards for service provision in colposcopy services 2012, Available at:, Accessed October 11. http://www.rcog.org.uk/womens-health/clinical-guidance/standards-service-provision-colposcopy-services.
61. National Cervical Screening Program (Australia) Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities 2005, Available at:, Accessed March16, 2011. http://www.health.gov.au/internet/screening/publishing.nsf/Content/guide.
62. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D., et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007, 197(4):346-355.
63. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008, 9(5):425-434.
64. Ghaem-Maghami S., Sagi S., Majeed G., Soutter W.P. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol 2007, 8(11):985-993.
65. Ghaem-Maghami S., Soutter W.P. Re: Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years. BJOG 2009, 116(3):465.
66. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003, 188(6):1383-1392.
67. Moore K., Cofer A., Elliot L., Lanneau G., Walker J., Gold M.A. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 2007, 197(2):141-146.
68. Howlett R.I., Marrett L.D., Innes M.K., Rosen B.P., McLachlin C.M. Decreasing incidence of cervical adenocarcinoma in Ontario: is this related to improved endocervical Pap test sampling?. Int J Cancer 2007, 120(2):362-367.
69. Etherington I.J., Luesley D.M. Adenocarcinoma in situ of the cervix- controversies in diagnosis and treatment. J Low Genit Tract Dis 2001, 5(2):94-98.
70. Cullimore J.E., Luesley D.M., Rollason T.P., Byrne P., Buckley C.H., Anderson M., et al. A prospective study of conization of the cervix in the management of cervical intraepithelial glandular neoplasia (CIGN)- a preliminary report. Br J Obstet Gynaecol 1992, 99(4):314-318.
71. Bertrand M., Lickrish G.M., Colgan T.J. The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment. Am J Obstet Gynecol 1987, 157(1):21-25.
72. Salani R., Puri I., Bristow R.E. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol 2009, 200(2):182-185.
73. Bryson P., Stulberg R., Shepherd L., McLelland K., Jeffrey J. Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS?. Gynecol Oncol 2004, 93(2):465-468.
74. Serati M., Uccella S., Laterza R.M., Salvatore S., Beretta P., Riva C., et al. Natural history of cervical intraepithelial neoplasia during pregnancy. Acta Obstet Gynecol Scand 2008, 87(12):1296-1300.
75. Fader A.N., Alward E.K., Niederhauser A., Chirico C., Lesnock J.L., Zwiesler D.J., et al. Cervical dysplasia in pregnancy: a multi-institutional evaluation. Am J Obstet Gynecol 2010, 203(2):113-116.
76. Soutter W.P., Sasieni P., Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006, 118(8):2048-2055.
77. Melnikow J., McGahan C., Sawaya G.F., Ehlen T., Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow- up from the British Columbia Cohort Study. J Natl Cancer Inst 2009, 101(10):721-728.
78. Soutter W.P., de Barros Lopes A., Fletcher A., Monaghan J.M., Duncan I.D., Paraskevaidis E., et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997, 349(9057):978-980.
79. Mitchell M.F., Tortolero-Luna G., Cook E., Whittaker L., Rhodes-Morris H., Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998, 92(5):737-744.
80. Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G., et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004, 30(2):205-211.
81. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(10):29-41. Suppl.
82. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124(3):516-520.
83. Chan B.K., Melnikow J., Slee C.A., Arellanes R., Sawaya G.F. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 2009, 200(4):422-429.
84. Kitchener H.C., Walker P.G., Nelson L., Hadwin R., Patnick J., Anthony G.B., et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008, 115(8):1001-1007.
85. Abrahamowicz M., Bentley J., Bessette P., Coutlee F., Ehlen T., Elit L., Fung-Kee-Fung M., Lau S., Mayrand M.H., Plante M., Sauthier P., Trottier H. Colposcopy vs. HPV testing to identity persistent pre-cancers post treatment: the CoHIPP trial. ClinicalTrials.gov Identifier: NCT01051895 2012, Full collaborator details available at:, Accessed on November 23. http://www.icid.com/files/HPV_Canadian_Network/HPV-research-directory_Final_Aug_2010.pdf.
86. ter Haar-van Eck S.A., Rischen-Vos J., Chadha-Ajwani S., Huikeshoven F.J. The incidence of cervical intraepithelial neoplasia among women with renal transplant in relation to cyclosporine. Br J Obstet Gynaecol 1995, 102(1):58-61.
87. David M., Olbrich C., Neuhaus R., Lichtenegger W. Occurrence of suspicious changes in cervix cytology in women after liver transplantation. Geburtshilfe Frauenheilkd 1995, 55(8):431-434.
88. Clifford G.M., Franceschi S. Cancer risk in HiV-infected persons: influence of CD4 (+) count. Future Oncol 2009, 5(5):669-678.
89. Denny L., Boa R., Williamson A.L., Allan B., Hardie D., Stan R., et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008, 111(6):1380-1387.
90. Boardman L.A., Cotter K., Raker C., Cu-Uvin S. Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology. Obstet Gynecol 2008, 112(2):238-243. (Pt 1).
91. Kitchener H., Nelson L., Adams J., Mesher D., Sasieni P., Cubie H., et al. Colposcopy is not necessary to assess the risk to the cervix in HiV- positive women: an international cohort study of cervical pathology in HiV-1 positive women. int J Cancer 2007, 121(11):2484-2491.
92. Foulot H., Heard i., Potard V., Costagliola D., Chapron C. Surgical management of cervical intraepithelial neoplasia in HiV-infected women. Eur J Obstet Gynecol Reprod Biol 2008, 141(2):153-157.
93. Farrell S., Roye C., Crane J., Davis D., Heywood M., Lalonde A., et al. SOGC Committee on Wait Times. Statement on wait times in obstetrics and gynaecology. SOGC Policy statement no. 204, March 208. J Obstet Gynaecol Can 2008, 30:248-270.
94. Kupets R., Paszat L. How are women with high grade Pap smear abnormalities managed? A population based study. Gynecol Oncol 2011, 121(3):499-504.
95. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G., Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003, 169:207-208.